Certara, Inc. ( (CERT) ) has released its Q2 earnings. Here is a breakdown of the information Certara, Inc. presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Certara, Inc. is a global leader in model-informed drug development, providing biosimulation software and services to biopharmaceutical companies, academic institutions, and regulatory agencies worldwide. In its second quarter of 2025 financial report, Certara, Inc. announced a 12% increase in revenue compared to the same period last year, reaching $104.6 million. The company also reported significant growth in its software revenue, which rose by 22%, and service revenue, which increased by 5%. Despite a net loss of $2.0 million, this marks an 84% improvement from the previous year’s second quarter net loss of $12.6 million.
Key financial highlights for Certara include an adjusted EBITDA of $31.9 million, a 21% increase from the prior year, and total bookings of $112.0 million, reflecting a 13% growth. The company’s software and services bookings also showed robust growth, driven by strong demand for its biosimulation solutions. Operating expenses decreased by $8.2 million, primarily due to lower transaction costs and a decrease in the change in fair value of contingent consideration.
Certara’s performance was bolstered by its core biosimulation software and quantitative systems pharmacology (QSP) services, which continued to attract significant interest from customers. The company’s management expressed confidence in its full-year plan, citing growing commercial momentum and sustained demand for its model-informed drug development solutions.
Looking ahead, Certara reiterated its full-year 2025 financial guidance, projecting revenue between $415 million and $425 million and an adjusted EBITDA margin of 30-32%. The company remains optimistic about its long-term growth prospects, supported by ongoing software product enhancements and new product introductions.